Zsolt Gaál

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 3K citations · Full text

Medicine, Endocrinology, Pharmacology +14

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais et al. · The Lancet · 2019 · 629 citations · Full text

Medicine, Endocrinology, Nephrology +15

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

Helena W. Rodbard, Julio Rosenstock, Luís Henrique Santos Canani et al. · Diabetes Care · 2019 · 446 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

A global study of the unmet need for glycemic control and predictor factors among patients with type 2 diabetes mellitus who have achieved optimal fasting plasma glucose control on basal insulin

D. Raccah, Engels Chou, Stephen Colagiuri et al. · Diabetes/Metabolism Research and Reviews · 2016 · 45 citations · Full text

Medicine, Endocrinology, Internal Medicine +17

Cardiometabolic risk and educational level in adult patients with type 1 diabetes

Judit Nádas, Zsuzsanna Putz, József Fövényi et al. · Acta Diabetologica · 2008 · 23 citations

Medicine, Health Education, Medical Education +15